Companies › BiomX
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BX004 Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa | PAER | Phase 2 | Chronic Pseudomonas Aeruginosa Infection | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06998043 | BX004 | Phase 2 | Chronic Pseudomonas Aeruginosa Infection | Infectious disease | Mar 2026 |
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Osivax Artcline Shanghai HEP Pharmaceutical Curevo Green Cross
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.